Statera Biopharma, Inc.

OTCPK:STAB Stock Report

Market Cap: US$7.3k

Statera Biopharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Statera Biopharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Sep 12

Statera Biopharma updates on Nasdaq Listing Status

Statera Biopharma (NASDAQ:STAB) provided an update on its request for a hearing before the Nasdaq Hearings Panel caused by delayed filing of its form 10-Q for the June quarter with the U.S. SEC in a timely manner. STAB had previously said that it had got non-compliance notices from Nasdaq regarding its inability to file its form 10-K for fiscal year 2021 and form 10-Q for the March quarter. The company timely requested a hearing and will request a further stay of any delisting action by Nasdaq pending the hearing, which is scheduled for October 6, 2022, and expiration of any extension that may be granted by the Panel. Last month, Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq. Shares are up 6.44% after-hours.
Seeking Alpha • Aug 25

Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq

Statera Biopharma (NASDAQ:STAB) on Thursday said it had got an expected additional notice of non-compliance from Nasdaq due to the company's failure to file its form 10-Q for the June quarter with the U.S. SEC in a timely manner. STAB had previously said that it had got non-compliance notices from Nasdaq regarding its inability to file its form 10-K for fiscal year 2021 and form 10-Q for the March quarter. Statera (STAB) said it plans to provide the exchange with an update regarding its compliance efforts. The company also said it plans to submit a timely plan to regain compliance. STAB stock was unchanged at $0.22 after hours.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Statera Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:STAB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20224-92-12-12N/A
6/30/20223-101-27-27N/A
3/31/20222-104-30-29N/A
12/31/20211-102-28-28N/A
9/30/20210-29-18-18N/A
6/30/2021N/A-22-10-10N/A
3/31/2021N/A-17-8-8N/A
12/31/2020N/A-12-5-5N/A
9/30/2020N/A-10-8-8N/A
12/31/2019N/A-300N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if STAB's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if STAB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if STAB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if STAB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if STAB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if STAB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 10:03
End of Day Share Price 2026/07/07 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Statera Biopharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.